In today’s briefing:
- Clinuvel Pharmaceuticals (CUV AU): Great Marketed Product; Strong Financials; Rich Pipeline
Clinuvel Pharmaceuticals (CUV AU): Great Marketed Product; Strong Financials; Rich Pipeline
- Since publishing my bullish insight on Clinuvel Pharmaceuticals (CUV AU) on April 29, the company reported ongoing positive financial performance and progress across its expanded clinical program.
- In Q4FY22, Clinuvel’s customer receipts surged 62% y/y to AUD24.05 million, mainly driven by rising clinical demand for Scenesse treatment.
- Clinuvel stands out amongst its domestic peers for being profitable and cash flow positive. The company has sufficient cash reserves to self-finance planned organic growth.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars